Clinical Trials Logo

Melanoma Metastatic clinical trials

View clinical trials related to Melanoma Metastatic.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05732805 Recruiting - Melanoma Clinical Trials

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

OCTAVA
Start date: August 2, 2022
Phase: Phase 3
Study type: Interventional

The aim of study is to investigate the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of BCD-217 followed by prolgolimab monotherapy versus prolgolimab monotherapy as first-line therapy in subjects with unresectable or metastatic melanoma.